Induction treatment regimens, n = 1179
| Treatment regimen . | No. of patients (%) . |
|---|---|
| IA | 551 (47) |
| DA | 68 (6) |
| FAI | 146 (12) |
| FA | 143 (12) |
| CA | 36 (3) |
| TA | 20 (2) |
| CAT | 204 (17) |
| Miscellaneous | 11 (1) |
| Treatment regimen . | No. of patients (%) . |
|---|---|
| IA | 551 (47) |
| DA | 68 (6) |
| FAI | 146 (12) |
| FA | 143 (12) |
| CA | 36 (3) |
| TA | 20 (2) |
| CAT | 204 (17) |
| Miscellaneous | 11 (1) |
IA indicates idarubicin + ara-C; DA, daunorubicin + ara-C; FAI, fludarabine + ara-C + idarubicin; FA, fludarabine + ara-C; CA, cyclophosphamide + ara-C; TA, topotecan + ara-C; and CAT, cyclophosphamide + ara-C + topotecan.